MTOR and hereditary hemorrhagic telangiectasia: We pharmacologically inhibited either global Vegf signalling or components of different pathways downstream of VEGFR2 (Kdrl) (Fig. S1) in zebrafish eng mutant and control embryos, and identified MEK/ERK (MAP3K/MAPK) and mTOR as synergistic therapeutic targets in HHT.